01 abril 2013

JACC: CARDIOVASCULAR INTERVENTIONS. Coronary Artery Aneurysms After Sirolimus-Eluting Stent Implantation. Multimodality Imaging Evaluation

Yusuke Fujino, MD⁎; Guilherme F. Attizzani, MD⁎; Sunao Nakamura, MD, PhD†; Marco A. Costa, MD, PhD⁎; Hiram G. Bezerra, MD, PhD⁎

A 57-year-old female underwent successful percutaneous coronary intervention (PCI) of the mid-distal left main coronary artery and the mid left anterior descending artery with 2 non-overlapping sirolimus-eluting stents with durable polymer (SES). Three years later, the patient was evaluated with multislice computed tomography due to recurrent chest pain.

01 abril 2013

JACC: CARDIOVASCULAR INTERVENTIONS. Percutaneous Reconstruction of Interrupted Aortic Arch in an Adult

Pravin K. Goel, DM; Nagaraja Moorthy, DM

Percutaneous stenting seems to be an attractive and preferred alternative to surgical therapy for treatment of aortic coarctation in the adolescent and young adult. However, percutaneous reconstruction of an interrupted aortic arch is challenging.

01 mayo 2013

JACC: CARDIOVASCULAR INTERVENTIONS. Coronary Obstruction Following Transcatheter Aortic Valve Implantation. A Systematic Review

Henrique Barbosa Ribeiro, MD; Luis Nombela-Franco, MD; Marina Urena, MD; Michael Mok, MD; Sergio Pasian, MD; Daniel Doyle, MD; Robert DeLarochellière, MD; Mélanie Côté, MSc; Louis Laflamme, MS; Hugo DeLarochellière, MS; Ricardo Allende, MD; Eric Dumont, MD; Josep Rodés-Cabau, MD

Objectives: This study sought to evaluate, through a systematic review of the published data, the main baseline characteristics, management, and clinical outcomes of patients suffering coronary obstruction as a complication of transcatheter aortic valve implantation (TAVI).

01 mayo 2013

JACC: CARDIOVASCULAR INTERVENTIONS. Impact of Post-Implant SAPIEN XT Geometry and Position on Conduction Disturbances, Hemodynamic Performance, and Paravalvular Regurgitation

Ronald K. Binder, MD; John G. Webb, MD; Stefan Toggweiler, MD; Melanie Freeman, MBBS; Marco Barbanti, MD; Alexander B. Willson, MBBS, MD; Donya Alhassan, MD; Cameron J. Hague, MD; David A. Wood, MD; Jonathon Leipsic, MD

Objectives: This report sought to study the impact of the balloon-expandable SAPIEN XT (Edwards Lifesciences, Irvine, California) transcatheter heart valve (THV) stent frame geometry and position on outcomes of transcatheter aortic valve replacement (TAVR).

01 mayo 2013

JACC: CARDIOVASCULAR INTERVENTIONS. Optimizing Outcome of Transcatheter Aortic Valve Replacement. It Is All About Geometry

Lutz Buellesfeld, MD

Aortic valve stenosis and its treatment is not a “black box.” It is not like a genetic disorder resulting in a complex syndrome that requires a very profound understanding and a sophisticated therapeutic approach; it is not like arterial hypertension, with a broad set of competing treatment alternatives and yet a somewhat unpredictable interindividual response to a chosen regimen, with a need for constant monitoring and adjustments. Aortic valve stenosis is a simple mechanical problem that requires a mechanical solution. That is the reason why surgical aortic valve replacement has been the successful gold standard treatment for decades in patients with symptomatic and severe aortic valve disease. This also explains why transcatheter aortic valve replacement (TAVR) could emerge as a suitable therapeutic alternative in the past decade and is now established for inoperable and high-risk surgical candidates

01 mayo 2013

JACC: CARDIOVASCULAR INTERVENTIONS. Post-Procedural Hypertension Following Transcatheter Aortic Valve Implantation. Incidence and Clinical Significance

Gidon Y. Perlman, MD; Sasa Loncar, MD; Arthur Pollak, MD; Dan Gilon, MD; Ronny Alcalai, MD; David Planer, MD; Chaim Lotan, MD; Haim D. Danenberg, MD

Objectives: This study sought to investigate the blood pressure (BP) response after transcatheter aortic valve implantation (TAVI) and its correlation with short- and mid-term clinical outcomes.

01 mayo 2013

JACC: CARDIOVASCULAR INTERVENTIONS. Renal Function–Based Contrast Dosing Predicts Acute Kidney Injury Following Transcatheter Aortic Valve Implantation

Masanori Yamamoto, MD, PhD⁎; Kentaro Hayashida, MD, PhD†; Gauthier Mouillet, MD⁎; Bernard Chevalier, MD†; Kentaro Meguro, MD, PhD⁎; Yusuke Watanabe, MD†; Jean-Luc Dubois-Rande, MD, PhD‡; Marie-Claude Morice, MD†; Thierry Lefèvre, MD†; Emmanuel Teiger, MD, PhD⁎

Objectives: This study sought to assess whether the volume of contrast media (CM) influences the occurrence of acute kidney injury (AKI) following transcatheter aortic valve implantation (TAVI).

01 mayo 2013

JACC: CARDIOVASCULAR INTERVENTIONS. Tumor Marker Carbohydrate Antigen 125 Predicts Adverse Outcome After Transcatheter Aortic Valve Implantation

Oliver Husser, MD⁎; Julio Núñez, MD‡; Eduardo Núñez, MD‡; Andreas Holzamer, MD§; Daniele Camboni, MD§; Andreas Luchner, MD⁎; Juan Sanchis, MD‡; Vicente Bodi, MD‡; Günter A.J. Riegger, MD⁎; Christof Schmid, MD§; Michael Hilker, MD§; Christian Hengstenberg, MD⁎

Objectives: This study sought to predict the value of tumor marker carbohydrate antigen 125 (CA125) before and after transcatheter aortic valve implantation (TAVI) for all-cause death and a composite endpoint of death, admission for heart failure, myocardial infarction, and stroke (major adverse cardiac events [MACE]).

01 mayo 2013

JACC: CARDIOVASCULAR INTERVENTIONS. Long-Term Outcomes After Surgical Versus Transcatheter Closure of Atrial Septal Defects in Adults

Mark A. Kotowycz, MD, MBA⁎; Judith Therrien, MD⁎; Raluca Ionescu-Ittu, PhD⁎; Colum G. Owens, MD⁎; Louise Pilote, MD, MPH, PhD†; Giuseppe Martucci, MD⁎; Christo Tchervenkov, MD⁎; Ariane J. Marelli, MD, MPH⁎

Objectives: The purpose of this study was to assess the comparative effectiveness and long-term safety of transcatheter versus surgical closure of secundum atrial septal defects (ASD) in adults.

01 mayo 2013

JACC: CARDIOVASCULAR INTERVENTIONS. Final 5-Year Outcomes From the Endeavor Zotarolimus-Eluting Stent Clinical Trial Program. Comparison of Safety and Efficacy With First-Generation Drug-Eluting and Bare-Metal Stents

David E. Kandzari, MD⁎; Martin B. Leon, MD†; Ian Meredith, MBBS, BSc, PhD‡; Jean Fajadet, MD§; William Wijns, MD, PhD∥; Laura Mauri, MD, MSc¶

Objectives: The aim of this study was to evaluate late safety and efficacy outcomes among patients enrolled in clinical trials comparing Endeavor zotarolimus-eluting stents (E-ZES) (Medtronic, Inc., Santa Rosa, California) with first-generation drug-eluting stents (DES) and bare-metal stents (BMS).

01 mayo 2013

JACC: CARDIOVASCULAR INTERVENTIONS. Modified Flower Petal Technique. A New Technique for the Treatment of Medina Type 1.1.1 Coronary Bifurcation Lesions

Murat Çaylı, MD; Durmuş Yıldıray Şahin, MD; Zafer Elbasan, MD; Mustafa Gür, MD; Cağlar Emre Çağlıyan, MD; Ali Kıvrak, MD; Taner Şeker, MD; Mehmet Ballı, MD

Objectives: This study sought to propose a new technique for the treatment of Medina type 1.1.1 bifurcation lesions.

01 mayo 2013

JACC: CARDIOVASCULAR INTERVENTIONS. Intracoronary Optical Coherence Tomography and Histology of Overlapping Everolimus-Eluting Bioresorbable Vascular Scaffolds in a Porcine Coronary Artery Model. The Potential Implications for Clinical Practice

Vasim Farooq, MB ChB⁎; Patrick W. Serruys, MD, PhD⁎; Jung Ho Heo, MD⁎; Bill D. Gogas, MD⁎; Yoshinobu Onuma, MD⁎; Laura E. Perkins, DVM, DACVP†; Roberto Diletti, MD⁎; Maria D. Radu, MD⁎; Lorenz Räber, MD⁎; Christos V. Bourantas, MD, PhD⁎; Yaojun Zhang, MD⁎; Eric van Remortel, BSc‡; Ravindra Pawar, BSc‡; Richard J. Rapoza, PhD†; Jennifer C. Powers, BS†; Heleen M.M. van Beusekom, PhD⁎; Hector M. Garcìa-Garcìa, MD, MSc, PhD⁎; Renu Virmani, MD, PhD§

Objectives: This study sought to assess the vascular response of overlapping Absorb stents compared with overlapping newer-generation everolimus-eluting metallic platform stents (Xience V [XV]) in a porcine coronary artery model.

01 mayo 2013

JACC: CARDIOVASCULAR INTERVENTIONS. Percutaneous Closure of a Pulmonary Arteriovenous Malformation in Young Patient With Cryptogenic Stroke

A 44-year-old woman had a transient ischemic attack in 2010 and a subsequent ischemic stroke (while on a regimen of aspirin therapy) in May 2012 with evidence of an ischemic cerebral lesion at magnetic resonance imaging. Thrombophilic screening tests showed factor V Leiden homozygosis. Transesophageal echocardiography revealed an atrial septum aneurysm without shunt during Valsalva maneuver after injection of agitated saline solution in the right antecubital vein; however, there was a late (after 5 cardiac cycles) appearance of agitated saline microbubbles in the left atrium through a pulmonary vein

01 mayo 2013

JACC: CARDIOVASCULAR INTERVENTIONS. Very Late Stent Thrombosis 5 Years After Implantation of a Sirolimus-Eluting Stent Observed by Angioscopy and Optical Coherence Tomography

Takayuki Ishihara, MD⁎; Masaki Awata, MD, PhD⁎; Masashi Fujita, MD, PhD⁎; Tetsuya Watanabe, MD, PhD⁎; Osamu Iida, MD⁎; Yoshio Ishida, MD, PhD⁎; Shinsuke Nanto, MD, PhD†; Masaaki Uematsu, MD, PhD⁎

Drug-eluting stents have dramatically reduced the rate of in-stent restenosis (1). However, very late stent thrombosis (VLST) is one of the clinical issues with regard to the safety of drug-eluting stents (2,3). To date there are no articles that report VLST evaluated by both angioscopy and optical coherence tomography (OCT). A 50-year-old man presented to the emergency department with chest pain. Five years earlier a 3.0 × 13 mm sirolimus-eluting stent (SES) was implanted in the left anterior descending artery

01 mayo 2013

JACC: CARDIOVASCULAR INTERVENTIONS. Transcatheter Device Closure of Atrial Septal Defects. A Safety Review

John Moore, MD, MPH⁎; Sanjeet Hegde, MD⁎; Howaida El-Said, MD⁎; Robert Beekman, MD†; Lee Benson, MD‡; Lisa Bergersen, MD, MPH§; Ralf Holzer, MD, MSc∥; Kathy Jenkins, MD, MPH§; Richard Ringel, MD¶; Jonathan Rome, MD#; Robert Vincent, MD⁎⁎; Gerard Martin, MD††

This review discusses the current safety issues related to U.S. Food and Drug Administration approved atrial septal defect devices and proposes a potential avenue to gather additional safety data including factors, which may be involved in device erosion.